(state or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Exhibit | ||||||||
No. | Description | |||||||
104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) |
KEROS THERAPEUTICS, INC. | ||||||||
By: | /s/ Jasbir Seehra | |||||||
Jasbir Seehra, Ph.D. Chief Executive Officer |
THREE MONTHS ENDED MARCH 31, | |||||||||||
2022 | 2021 | ||||||||||
OPERATING EXPENSES: | |||||||||||
Research and development | (18,078) | (11,495) | |||||||||
General and administrative | (6,048) | (4,274) | |||||||||
Total operating expenses | (24,126) | (15,769) | |||||||||
LOSS FROM OPERATIONS | (24,126) | (15,769) | |||||||||
OTHER EXPENSE, NET | |||||||||||
Interest expense, net | (1) | (1) | |||||||||
Other expense, net | (59) | (65) | |||||||||
Total other expense, net | (60) | (66) | |||||||||
Loss before income taxes | (24,186) | (15,835) | |||||||||
Income tax (provision) benefit | — | (50) | |||||||||
Net loss | $ | (24,186) | $ | (15,885) | |||||||
Net loss attributable to common stockholders—basic and diluted | $ | (24,186) | $ | (15,885) | |||||||
Net loss per share attributable to common stockholders—basic and diluted | $ | (1.01) | $ | (0.68) | |||||||
Weighted-average common stock outstanding—basic and diluted | 23,993,698 | 23,229,794 |
MARCH 31, 2022 | DECEMBER 31, 2021 | ||||||||||
ASSETS | |||||||||||
CURRENT ASSETS: | |||||||||||
Cash and cash equivalents | 228,586 | 230,042 | |||||||||
Accounts receivable | — | 18,000 | |||||||||
Prepaid expenses and other current assets | 2,634 | 3,398 | |||||||||
Total current assets | 231,220 | 251,440 | |||||||||
Operating lease right-of-use assets | 864 | 1,067 | |||||||||
Property and equipment, net | 1,456 | 1,335 | |||||||||
Restricted cash | 1,327 | 1,327 | |||||||||
Other long-term asset | 275 | 82 | |||||||||
TOTAL ASSETS | 235,142 | 255,251 | |||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||
CURRENT LIABILITIES: | |||||||||||
Accounts payable | 3,064 | 3,645 | |||||||||
Current portion of operating lease liabilities | 884 | 862 | |||||||||
Accrued expenses and other current liabilities | 7,700 | 7,339 | |||||||||
Total current liabilities | 11,648 | 11,846 | |||||||||
Operating lease liabilities, net of current portion | — | 231 | |||||||||
Total liabilities | 11,648 | 12,077 | |||||||||
STOCKHOLDERS' EQUITY: | |||||||||||
Common stock, par value of $0.0001 per share; 200,000,000 authorized as of March 31, 2022 and December 31, 2021, respectively; 24,003,103 and 23,974,834 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 2 | 2 | |||||||||
Additional paid-in capital | 371,433 | 366,927 | |||||||||
Accumulated deficit | (147,941) | (123,755) | |||||||||
Total stockholders' equity | 223,494 | 243,174 | |||||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 235,142 | 255,251 |
Cover |
Sep. 02, 2021 |
Aug. 04, 2021 |
---|---|---|
Cover [Abstract] | ||
Document Type | 8-K | |
Document Period End Date | May 05, 2022 | |
Entity Registrant Name | Keros Therapeutics, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity File Number | 001-39264 | |
Entity Tax Identification Number | 81-1173868 | |
Entity Address, Address Line One | 99 Hayden Avenue | |
Entity Address, Address Line Two | Suite 120 | |
Entity Address, Address Line Three | Building E | |
Entity Address, City or Town | Lexington | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 02421 | |
City Area Code | 617 | |
Local Phone Number | 314-6297 | |
Written Communications | false | |
Soliciting Material | false | |
Pre-commencement Tender Offer | false | |
Pre-commencement Issuer Tender Offer | false | |
Title of 12(b) Security | Common Stock, $0.0001 par value per share | |
Trading Symbol | KROS | |
Security Exchange Name | NASDAQ | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Central Index Key | 0001664710 | |
Amendment Flag | false |
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end